• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心力衰竭管理的范围

The Spectrum of Heart Failure Management.

作者信息

Ghani Usman, Farooq Omer, Aziz Sundal, Alam Sundus, Khan Muhammad Junaid, Rahim Omar

机构信息

Cardiology, Northwest General Hospital and Research Center, Peshawar, PAK.

Internal Medicine, Ascension Saint Francis Hospital, Evanston, USA.

出版信息

Cureus. 2023 Jun 18;15(6):e40587. doi: 10.7759/cureus.40587. eCollection 2023 Jun.

DOI:10.7759/cureus.40587
PMID:37469814
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10353487/
Abstract

Heart failure, a complex cardiovascular condition, is a huge burden on patients, caregivers, and healthcare systems and it is prevalent worldwide. Heart failure is caused by a wide variety of underlying conditions that include both cardiac and non-cardiac pathologies. Identifying the underlying cause enables us to apply etiology-based interventions. The spectrum of heart failure management ranges from classification to transplantation. In addition to its classification and monitoring, this article reviews various management strategies, including both conventional methods and the latest innovations. These include lifestyle interventions, pharmacotherapy, device therapy, transplantation, and regenerative medicine.

摘要

心力衰竭是一种复杂的心血管疾病,给患者、护理人员和医疗保健系统带来了巨大负担,并且在全球范围内普遍存在。心力衰竭由多种潜在疾病引起,包括心脏和非心脏病理状况。确定潜在病因有助于我们采取基于病因的干预措施。心力衰竭的管理范围从分类到移植。除了分类和监测之外,本文还综述了各种管理策略,包括传统方法和最新创新。这些策略包括生活方式干预、药物治疗、器械治疗、移植和再生医学。

相似文献

1
The Spectrum of Heart Failure Management.心力衰竭管理的范围
Cureus. 2023 Jun 18;15(6):e40587. doi: 10.7759/cureus.40587. eCollection 2023 Jun.
2
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
What Is the Status of Regenerative Therapy in Heart Failure?心力衰竭的再生治疗现状如何?
Curr Cardiol Rep. 2021 Aug 19;23(10):146. doi: 10.1007/s11886-021-01575-3.
4
The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol.以学校为基础的家庭哮喘教育项目对5至18岁确诊哮喘儿童生活质量和哮喘发作次数的有效性:一项系统评价方案
JBI Database System Rev Implement Rep. 2015 Oct;13(10):69-81. doi: 10.11124/jbisrir-2015-2335.
5
6
Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.增强型体外反搏(EECP):基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(5):1-70. Epub 2006 Mar 1.
7
Regenerative Therapy for Patients with Congenital Heart Disease.先天性心脏病患者的再生疗法
Keio J Med. 2019 Jun 25;68(2):29-38. doi: 10.2302/kjm.2018-0002-IR. Epub 2018 Jun 19.
8
Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network.心力衰竭的临床药学服务:美国心力衰竭学会和美国临床药学学院心脏病学实践与研究网络的意见文件。
J Card Fail. 2013 May;19(5):354-69. doi: 10.1016/j.cardfail.2013.02.002. Epub 2013 Apr 6.
9
Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.第二代和第三代左心室辅助装置作为适合心脏移植的成人移植桥接或替代治疗的临床效果和成本效益:系统评价和成本效益模型。
Health Technol Assess. 2013 Nov;17(53):1-499, v-vi. doi: 10.3310/hta17530.
10
New treatment strategy for severe heart failure: combination of ventricular assist device and regenerative therapy.严重心力衰竭的新治疗策略:心室辅助装置与再生疗法的联合应用。
J Artif Organs. 2021 Mar;24(1):1-5. doi: 10.1007/s10047-020-01185-w. Epub 2020 Jun 20.

本文引用的文献

1
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南:美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
2
Interventional heart failure therapy: A new concept fighting against heart failure.介入性心力衰竭治疗:心力衰竭治疗的新理念。
J Cardiol. 2022 Aug;80(2):101-109. doi: 10.1016/j.jjcc.2021.11.018. Epub 2021 Dec 16.
3
Gene therapy for ischaemic heart disease and heart failure.基因治疗缺血性心脏病和心力衰竭。
J Intern Med. 2021 Sep;290(3):567-582. doi: 10.1111/joim.13308. Epub 2021 May 25.
4
Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017.1990 年至 2017 年,195 个国家和地区心力衰竭的负担及其根本原因。
Eur J Prev Cardiol. 2021 Dec 29;28(15):1682-1690. doi: 10.1093/eurjpc/zwaa147.
5
Remote Monitoring in Chronic Heart Failure Patients: Is Non-Invasive Remote Monitoring the Way to Go?远程监测在慢性心力衰竭患者中的应用:无创远程监测是否可行?
Sensors (Basel). 2021 Jan 28;21(3):887. doi: 10.3390/s21030887.
6
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
7
Cardiac biomarkers of heart failure in chronic kidney disease.慢性肾脏病中心力衰竭的心脏生物标志物
Clin Chim Acta. 2020 Nov;510:298-310. doi: 10.1016/j.cca.2020.07.040. Epub 2020 Jul 23.
8
Permanent Implantable Cardiac Support Systems.永久性植入式心脏支持系统。
Dtsch Arztebl Int. 2019 Dec 13;116(50):843-848. doi: 10.3238/arztebl.2019.0843.
9
The Future of Wearables in Heart Failure Patients.可穿戴设备在心力衰竭患者中的未来应用。
JACC Heart Fail. 2019 Nov;7(11):922-932. doi: 10.1016/j.jchf.2019.08.008.
10
Stem Cell and Left Ventricular Assist Device Combination Therapy.干细胞与左心室辅助装置联合治疗。
Circ Heart Fail. 2019 Feb;12(2):e005454. doi: 10.1161/CIRCHEARTFAILURE.118.005454.